This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Clovis' Rubraca Gets Nod as Maintenance Therapy in Europe
by Zacks Equity Research
Clovis Oncology (CLVS) announces approval of label expansion for Rubraca to include maintenance treatment of ovarian cancer patients in second-line setting in Europe. Shares up.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $40.64, marking a -0.76% move from the previous day.
Pharma Stock Roundup: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV
by Zacks Equity Research
J&J (JNJ) and Bristol-Myers (BMY) kick off earnings for pharma sector. Lilly (LLY) and AbbVie (ABBV) announce failure of late-stage studies.
Pfizer (PFE) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive Q4 sales, genericization of key drugs and weak sales in the EH segment will hurt the same.
Healthcare ETFs in Focus Ahead of Q4 Earnings
by Sweta Killa
With lower negative earnings revisions, the healthcare sector is expected to witness earnings growth of 7.7% in the fourth quarter, suggesting continued outperformance for healthcare ETFs.
The Zacks Analyst Blog Highlights: Pfizer, Biogen, Schwab, Sysco and Philips
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Biogen, Schwab, Sysco and Philips
Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY
by Zacks Equity Research
Pfizer's (PFE) tafamidis application gets FDA's priority review. Regulatory updates for Roche's (RHHBY) and Bristol-Myers'(BMY) cancer combination drugs in focus.
Dow 30 Stock Roundup: JPM & AXP Earnings Disappoint, GS & UNH Impress
by Swarup Gupta
The index enjoyed another strong week of gains, increasing over three straight sessions.
Baxter (BAX) Gains From Sharesource's Global Success Rates
by Zacks Equity Research
Baxter's (BAX) PD platform sees increased demand, owing to rising CKD rates around the world.
Top Stock Reports for Pfizer, Biogen & Schwab
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), Biogen (BIIB) and Schwab (SCHW).
J&J (JNJ) to Commence Pharma Q4 Earnings: What to Expect
by Zacks Equity Research
J&J's (JNJ) Pharmaceuticals segment is likely to face difficult comparisons in fourth quarter.
Pfizer (PFE) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $42.73 in the latest trading session, marking a +0.85% move from the prior day.
Bristol-Myers' Drug Combination Gets EU Nod for Renal Cancer
by Zacks Equity Research
Bristol-Myers (BMY) gets EU approval for the immuno-oncology combination of Opdivo and low-dose Yervoy for the first-line treatment of patients with intermediate- and poor-risk advanced RCC.
Pfizer Gets FDA's Priority Review for Rare Disease Candidate
by Zacks Equity Research
FDA grants priority review to Pfizer's (PFE) regulatory filing looking for approval of pipeline candidate, tafamidis to treat transthyretin amyloid cardiomyopathy.
NASH Space in Focus in 2019 as Firms Look to Diversify
by Zacks Equity Research
NASH is a highly lucrative market with blockbuster potential. Hence, we take a look at some of the companies in this space.
Amarin (AMRN) Stock Up on Rumors of Acquisition by Pfizer
by Zacks Equity Research
Amarin (AMRN) shares rally on rumors of its potential; acquisition by large pharmaceutical company, Pfizer. Speculations are rife about rising M&A activity in the pharma space.
Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet
by Zacks Equity Research
Lilly (LLY) is spending $8 billion to buy small cancer biotech Loxo Oncology. Big Pharma CEOs hint at spur in M&A activity in 2019.
4 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019
by Kinjel Shah
Here we present four therapeutic areas whose pipeline developments are expected to garner a lot of interest in 2019.
Athenex Completes Enrollment Target for Breast Cancer Study
by Zacks Equity Research
Athenex (ATNX) has completed target enrollment in the Oraxol phase III study in metastatic breast cancer on schedule.
Big Pharma CEOs Indicate More M&A Deals at JP Morgan Meeting
by Zacks Equity Research
Big pharma CEOs hint at spur in M&A activity in 2019 at the 37th J.P. Morgan Healthcare Conference.
Dogs of the Dow Win in 2018: Will ETFs See Success in 2019?
by Sanghamitra Saha
Dogs of the Dow beat the broader market in 2018. Will Dogs ETFs be able to taste success this year too?
Pfizer (PFE) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $43.23, marking a +0.53% move from the previous day.
Aerie's Rhopressa Succeeds in Study on Japanese Patients
by Zacks Equity Research
Aerie (AERI) announces encouraging top-line results from its pilot phase II study of netarsudil ophthalmic solution in a Japan.
Biogen Inks Two Deals to Make Drugs for Neurological Diseases
by Zacks Equity Research
Biogen (BIIB) signs deals with C4 Therapeutics and Skyhawk Therapeutics to develop potential therapies for Alzheimer's disease (AD), Parkinson's disease and other neurological diseases.
Company News For Jan 7, 2019
by Zacks Equity Research
Companies In The News Are: GME,CEO,TSLA,PFE